• 1. Alt-proteins: A promising future
• 2. An amino group functionalized metal–organic framework as a luminescent probe for highly selective sensing of Fe3+ ions?
  Zhonghua Xiang,Chuanqi Fang,Sanhua Leng,Dapeng Cao J. Mater. Chem. A, 2014,2, 7662-7665
• 3. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. Aggregation-induced emission leading to two distinct emissive species in the solid-state structure of high-dipole organic chromophores?
  Felix Witte,Philipp Rietsch,Nithiya Nirmalananthan-Budau,Florian Weigert,Jan P. G?tze,Ute Resch-Genger,Siegfried Eigler,Beate Paulus Phys. Chem. Chem. Phys., 2021,23, 17521-17529

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenethylamines

Introduction to 3-2-(methylamino)ethylphenol hydrobromide (CAS No. 61186-06-9)

3-2-(methylamino)ethylphenol hydrobromide, identified by its CAS number 61186-06-9, is a compound of significant interest in the field of pharmaceutical chemistry and biochemistry. This compound, a hydrobromide salt, has garnered attention due to its structural properties and potential applications in drug development. The presence of both aromatic and amine functional groups makes it a versatile intermediate in the synthesis of various pharmacologically active molecules.

The molecular structure of 3-2-(methylamino)ethylphenol hydrobromide consists of a phenolic ring substituted with an ethyl chain that terminates in a methylamino group. This configuration imparts unique chemical reactivity, making it a valuable building block for medicinal chemists. The hydrobromide form enhances the solubility and stability of the compound, facilitating its use in various synthetic protocols.

In recent years, there has been growing interest in exploring the pharmacological potential of compounds with similar structural motifs. The amine and phenol functionalities are known to participate in diverse biological interactions, including binding to enzymes and receptors. This has prompted researchers to investigate 3-2-(methylamino)ethylphenol hydrobromide for its potential role in developing new therapeutic agents.

One of the most promising areas of research involving 3-2-(methylamino)ethylphenol hydrobromide is its application in the synthesis of kinase inhibitors. Kinases are enzymes that play a crucial role in cell signaling pathways, and their dysregulation is associated with various diseases, including cancer. By designing molecules that specifically target kinases, researchers aim to develop drugs that can modulate these pathways effectively. The structural features of 3-2-(methylamino)ethylphenol hydrobromide make it a suitable candidate for such applications.

Recent studies have demonstrated the efficacy of derivatives of 3-2-(methylamino)ethylphenol hydrobromide in inhibiting specific kinases. For instance, modifications to the phenolic ring and the amine group have led to compounds with enhanced binding affinity and selectivity. These findings highlight the importance of optimizing the structure-activity relationships (SAR) to develop potent kinase inhibitors.

The synthesis of 3-2-(methylamino)ethylphenol hydrobromide involves multi-step organic reactions, typically starting from commercially available precursors. The process requires careful control of reaction conditions to ensure high yield and purity. Advances in synthetic methodologies have enabled more efficient and scalable production methods, making it feasible to conduct large-scale studies and clinical trials.

In addition to its role in kinase inhibition, 3-2-(methylamino)ethylphenol hydrobromide has shown potential in other therapeutic areas. Its ability to interact with biological targets suggests applications in treating neurological disorders, inflammation, and infectious diseases. Further research is needed to fully elucidate its mechanism of action and therapeutic potential.

The development of new drugs is a complex process that involves extensive testing for efficacy, safety, and pharmacokinetics. Preclinical studies using 3-2-(methylamino)ethylphenol hydrobromide derivatives have provided valuable insights into their biological activity and potential side effects. These studies are crucial for determining the feasibility of moving into clinical trials and eventually bringing new treatments to patients.

The pharmaceutical industry continues to invest heavily in research aimed at discovering new active ingredients like 3-2-(methylamino)ethylphenol hydrobromide. Collaborative efforts between academic institutions and pharmaceutical companies are essential for translating laboratory findings into viable therapeutic options. By leveraging cutting-edge technologies and innovative approaches, researchers hope to accelerate the development of novel drugs that address unmet medical needs.

In conclusion, 3-2-(methylamino)ethylphenol hydrobromide(CAS No. 61186-06-9) is a compound with significant potential in pharmaceutical research. Its unique structural features make it a valuable intermediate for synthesizing biologically active molecules. Ongoing studies are exploring its applications in kinase inhibition and other therapeutic areas, paving the way for new treatments for various diseases.

• 501-15-5(4-2-(methylamino)ethylbenzene-1,2-diol)
• 1346598-66-0(Hordenine-d6)
• 539-15-1(Hordenine)
• 62493-39-4(Hordenine)
• 370-98-9(N-Methyl-p-tyramine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)